Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of nisoldipine
extended-release 30 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release
30 mg tablet (manufactured for First Horizon) following a single, oral 30 mg (1 × 30 mg
tablet) dose administration in healthy adult subjects under fasting conditions.